COMPOSITIONS AND METHODS FOR SIMULTANEOUS BIVALENT AND MONOVALENT CO-ENGAGEMENT OF ANTIGENS
First Claim
Patent Images
1. An antibody analog comprising:
- a) a first heavy chain and an associated light chain, wherein said first heavy and light chains form a first antigen binding site, wherein the C-terminus of the CH3 domain of said first heavy chain is covalently attached to a C-terminal variable heavy domain;
b) a second heavy chain and an associated light chain, wherein said second heavy and light chains form a second antigen binding site, wherein the C-terminus of the CH3 domain of said second heavy chain is covalently attached to a C-terminal variable light domain;
such that said C-terminal variable heavy and light domains form a third antigen binding site.
1 Assignment
0 Petitions
Accused Products
Abstract
Immunoglobulin compositions that simultaneously co-engage antigens, where one of the antigens is bound bivalently and the other antigen is bound monovalently. The novel immunoglobulins described preferably utilize heterodimeric Fc regions.
-
Citations
17 Claims
-
1. An antibody analog comprising:
-
a) a first heavy chain and an associated light chain, wherein said first heavy and light chains form a first antigen binding site, wherein the C-terminus of the CH3 domain of said first heavy chain is covalently attached to a C-terminal variable heavy domain; b) a second heavy chain and an associated light chain, wherein said second heavy and light chains form a second antigen binding site, wherein the C-terminus of the CH3 domain of said second heavy chain is covalently attached to a C-terminal variable light domain;
such that said C-terminal variable heavy and light domains form a third antigen binding site. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12)
-
-
13. An antibody analog comprising:
-
a) a first heavy chain comprising a variable heavy domain; b) a second chain comprising the Fc domain of a heavy chain covalently linked to a light chain, wherein said first heavy chain and said second chain form a first antigen binding site; wherein the C-terminus of the CH3 domain of said first heavy chain is covalently attached to a variable heavy domain and the C-terminus of the CH3 domain of said second chain is covalently attached to a variable light domain, such that said variable heavy and light domains form a second antigen binding site. - View Dependent Claims (14, 15, 16, 17)
-
Specification